VistaGen Therapeutics, Inc. (VTGN) Financial Statements (2024 and earlier)
Company Profile
Business Address |
343 ALLERTON AVENUE SOUTH SAN FRANCISCO, CA 94080 |
State of Incorp. | NV |
Fiscal Year End | March 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
9/30/2023 MRQ | 3/31/2023 | 12/31/2022 MRQ | 3/31/2022 | 3/31/2021 | 3/31/2020 | 3/31/2019 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 16,638 | 25,037 | 68,135 | 103,108 | 1,355 | 13,100 | |||
Cash and cash equivalents | 16,638 | 25,037 | 68,135 | 103,108 | 1,355 | 13,100 | |||
Receivables | 41 | 300 | |||||||
Prepaid expense | 122 | 96 | |||||||
Capitalized contract cost | 67 | ||||||||
Deferred costs | 67 | 67 | 117 | 134 | |||||
Other undisclosed current assets | 803 | 886 | 2,746 | 713 | 225 | 155 | |||
Total current assets: | 17,507 | 26,058 | 70,998 | 104,118 | 1,580 | 13,651 | |||
Noncurrent Assets | |||||||||
Operating lease, right-of-use asset | 2,260 | 2,364 | 2,662 | 3,220 | 3,580 | ✕ | |||
Property, plant and equipment | 507 | 541 | 414 | 367 | 210 | 313 | |||
Capitalized contract cost, net | 234 | ||||||||
Deposits noncurrent assets | 101 | 101 | 101 | ||||||
Deferred costs | 218 | 234 | 146 | 234 | |||||
Other undisclosed noncurrent assets | 496 | 177 | 322 | 343 | 403 | 48 | |||
Total noncurrent assets: | 3,582 | 3,651 | 3,645 | 4,164 | 4,192 | 361 | |||
TOTAL ASSETS: | 21,089 | 29,709 | 74,643 | 108,281 | 5,772 | 14,012 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities | 3,261 | 2,684 | 4,154 | 2,401 | 2,398 | 2,741 | |||
Employee-related liabilities | ✕ | ✕ | ✕ | 66 | |||||
Accounts payable | 2,473 | 1,599 | 2,759 | 838 | 1,837 | 1,055 | |||
Accrued liabilities | 787 | 1,085 | 1,329 | 1,563 | 562 | 1,686 | |||
Deferred revenue | 714 | 712 | 1,244 | 1,420 | ✕ | ||||
Debt | 2 | 2 | 3 | 60 | 60 | ||||
Other undisclosed current liabilities | 591 | 890 | 367 | 365 | 313 | ||||
Total current liabilities: | 4,567 | 4,287 | 5,765 | 4,189 | 2,771 | 2,801 | |||
Noncurrent Liabilities | |||||||||
Long-term debt and lease obligation | 7 | 8 | 2,605 | 3,351 | 3,719 | 6 | |||
Capital lease obligations | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 6 | ||
Finance lease, liability | 7 | 8 | 3 | ✕ | |||||
Liabilities, other than long-term debt | 4,434 | 4,739 | 1,558 | 2,490 | 381 | ||||
Deferred revenue | 2,315 | 2,492 | 1,558 | 2,490 | ✕ | ||||
Deferred rent credit | 381 | ||||||||
Operating lease, liability | 2,120 | 2,247 | 2,605 | 3,351 | 3,716 | ✕ | |||
Other undisclosed noncurrent liabilities | 6,273 | 1,296 | 3,748 | ||||||
Total noncurrent liabilities: | 4,442 | 4,747 | 4,163 | 12,114 | 8,730 | 4,136 | |||
Total liabilities: | 9,009 | 9,034 | 9,928 | 16,303 | 11,502 | 6,937 | |||
Equity | |||||||||
Equity, attributable to parent, including: | 12,080 | 20,675 | 64,715 | 91,979 | (5,729) | 7,075 | |||
Common stock | 7 | 207 | 207 | 181 | 49 | 43 | |||
Treasury stock, value | (3,968) | (3,968) | (3,968) | (3,968) | (3,968) | (3,968) | |||
Additional paid in capital | 342,893 | 339,060 | 336,081 | 315,603 | 200,093 | 192,130 | |||
Accumulated deficit | (326,852) | (314,625) | (267,604) | (219,842) | (201,907) | (181,133) | |||
Other undisclosed equity, attributable to parent | 4 | 4 | 4 | ||||||
Total equity: | 12,080 | 20,675 | 64,715 | 91,979 | (5,729) | 7,075 | |||
TOTAL LIABILITIES AND EQUITY: | 21,089 | 29,709 | 74,643 | 108,281 | 5,772 | 14,012 |
Income Statement (P&L) ($ in thousands)
9/30/2023 TTM | 3/31/2023 | 12/31/2022 TTM | 3/31/2022 | 3/31/2021 | 3/31/2020 | 3/31/2019 | ||
---|---|---|---|---|---|---|---|---|
Revenues | (227) | 772 | 1,109 | 1,090 | ||||
Gross profit: | (227) | 772 | 1,109 | 1,090 | ||||
Operating expenses | (59,041) | (83,152) | (48,888) | (19,023) | (20,802) | (24,556) | ||
Other undisclosed operating income (loss) | (0) | (713) | (0) | |||||
Operating loss: | (59,268) | (83,093) | (47,779) | (17,934) | (20,802) | (24,556) | ||
Interest and debt expense | (31) | |||||||
Other undisclosed income from continuing operations before equity method investments, income taxes | 6 | |||||||
Loss from continuing operations before equity method investments, income taxes: | (59,268) | (83,087) | (47,779) | (17,934) | (20,802) | (24,587) | ||
Other undisclosed income from continuing operations before income taxes | 26 | 34 | 20 | 2 | 30 | |||
Loss from continuing operations before income taxes: | (59,242) | (83,054) | (47,759) | (17,932) | (20,771) | (24,587) | ||
Income tax expense | (6) | (6) | (3) | (3) | (3) | (3) | ||
Loss from continuing operations: | (59,248) | (83,060) | (47,762) | (17,934) | (20,774) | (24,590) | ||
Loss before gain (loss) on sale of properties: | ✕ | ✕ | (73,299) | (47,762) | (17,934) | (20,774) | (24,590) | |
Net loss attributable to parent: | (59,248) | (83,060) | (47,762) | (17,934) | (20,774) | (24,590) | ||
Preferred stock dividends and other adjustments | 92 | (945) | ||||||
Other undisclosed net loss available to common stockholders, basic | (24,386) | (1,264) | (1,140) | |||||
Net loss available to common stockholders, diluted: | (59,248) | (82,968) | (48,708) | (42,320) | (22,038) | (25,730) |
Comprehensive Income ($ in thousands)
9/30/2023 TTM | 3/31/2023 | 12/31/2022 TTM | 3/31/2022 | 3/31/2021 | 3/31/2020 | 3/31/2019 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (59,248) | (83,060) | (47,762) | (17,934) | (20,774) | (24,590) | ||
Comprehensive loss, net of tax, attributable to parent: | (59,248) | (83,060) | (47,762) | (17,934) | (20,774) | (24,590) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.